Debt-to-equity of Vincerx Pharma, Inc. from 30 Sep 2020 to 31 Mar 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Vincerx Pharma, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2020 to 31 Mar 2025.
  • Vincerx Pharma, Inc. Debt-to-equity for the quarter ending 31 Mar 2025 was 68%, a 16% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Vincerx Pharma, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q1 2025 68% -12% -16% 31 Mar 2025
Q4 2024 108% +60% +123% 31 Dec 2024
Q3 2024 87% +49% +130% 30 Sep 2024
Q2 2024 85% +55% +190% 30 Jun 2024
Q1 2024 80% +57% +241% 31 Mar 2024
Q4 2023 49% +29% +152% 31 Dec 2023
Q3 2023 38% +20% +111% 30 Sep 2023
Q2 2023 29% +8.8% +43% 30 Jun 2023
Q1 2023 23% +1.2% +5.4% 31 Mar 2023
Q4 2022 19% -14% -41% 31 Dec 2022
Q3 2022 18% -35% -66% 30 Sep 2022
Q2 2022 20% -56% -73% 30 Jun 2022
Q1 2022 22% -131% -85% 31 Mar 2022
Q4 2021 33% -161% -83% 31 Dec 2021
Q3 2021 53% +1940% 30 Sep 2021
Q2 2021 77% 30 Jun 2021
Q1 2021 153% 31 Mar 2021
Q4 2020 194% 31 Dec 2020
Q3 2020 -1887% 30 Sep 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.